“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

US pharma major AbbVie announced positive top-line results from its pivotal Phase III TEMPO-2 trial evaluating ...

AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said ...

For 50 years, it has been supposed that partial agonists — ligands that can fully occupy receptors but produce a submaximal response — that act at ion channels evoke a small response because ...

AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational ...

Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...

AbbVie (ABBV) announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose ...

Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a selective ...

The controversy over the diabetes drug rosiglitazone (Avandia; GlaxoSmithKline), a peroxisome proliferator-activated receptor-γ agonist, has undermined confidence in developing drugs that target ...